Everest Medicines has entered into a share purchase agreement to acquire Hasten Biopharma for a total consideration of USD 250 million. The acquisition, to be paid in three tranches, provides Everest with commercial rights to 14 chronic disease products across multiple Asia-Pacific markets. Hasten generated normalised revenue of USD 82.2 million and an EBITDA of USD 27.3 million for the fiscal year ending 31 December 2025.

The deal includes a 120-person sales and commercial team, establishing an instant pan-Asia commercialisation platform for Everest. The transaction aligns with Everest's strategy to expand its presence in the chronic disease sector across the APAC region and positions the company as a partner of choice for global innovative assets seeking market access in China and Asia. A refundable deposit of RMB 200 million, paid under a previous letter of intent, will be returned to Everest after the deal closes.

PharmCube's NextBiopharm® database shows that Everest's pipeline focuses on oncology. Click here to request a free trial for NextBiopharm®.